Who is planning to go to HDSA's National Convention in Los Angeles this June? Haven't really thought about it yet? Well you should, either way... Because all of... us will be there!
If you're not sure what we are talking about, reach out to one of the board members to get more information about Convention and other NYA events coming up for 2018!
The NYA offers full and partial scholarships for people age 29 and under who want to attend National Convention but may not be able to afford the trip. Check out the link below to apply and ask one of us if you have any questions!
Letter from Louise Vetter - HDSA
Dear HD Community Member:
As you may know, some members of the HD community are facing significant challenges right now in secu...ring financial assistance to help off-set the sometimes large co-pays for chorea management prescriptions.
Caring Voice Coalition, the largest supporter of such aid, has announced that it will not be awarding any financial assistance in 2018. Visit www.caringvoice.org for more information on this decision. (Please note, we have been assured that CVC's disability assistance and health insurance counseling programs continue unaffected by this decision.) In addition, we are aware that the HealthWell Foundation's movement disorders fund & Huntington's disease fund have been depleted.
Prescriptions co-pays vary greatly based on health insurance provider. While these costs have always been a concern, we have been grateful for the financial assistance programs that have helped alleviate the burden and close the gap between price and access.
Since the Caring Voice announcement, HDSA has been contacting all of our partners and known HD assistance programs to identify potential resources for the nationwide HD community. It is important to note that unfortunately, due to significant infrastructure and complicated legal requirements necessary to implement a program such as this, HDSA cannot respond to this urgent need. As a result, our role is to advocate for the regulators and manufacturers alike to ensure mechanisms are in place to support HD families in accessing their prescribed medications.
Following are the phone numbers for the primary prescription resource services of which we are aware:
Xenazine Information Center:
For patients prescribed Xenazine, which is manufactured by Lundbeck.
Austedo Shared Solutions Hotline
For patients prescribed Austedo, which is manufactured by Teva.
Biotek reMedys Foundation
For some patients receiving tetrabenazine (eligibility for support may be affected by insurance coverage and related variables).
Additionally, the National Organization for Rare Disorders (NORD) continues to have a co-pay assistance fund for patients being treated for chorea. We are aware that they are slow to onboard 2018 patients, but you may contact them at National Organization for Rare Disorders 1-855-864-4027 or by emailing email@example.com.
Most importantly we encourage you to talk with your clinician about difficulties you are facing accessing your prescription to see what options and solutions they may be able to identify.
We are hopeful that new funds will be identified in the coming weeks, and you can be sure that we will share that news with you as soon as it becomes available. In the meantime, HDSA's network of social workers is also available to help you problem solve.
Thank you for your patience as we work together through this difficult time.
President & Chief Executive Officer
Huntington's Disease Society of America
Like us on Facebook
Follow us on Twitter
View our videos on YouTube
View on Instagram
#HuntingtonsDisease news from the Rare Disease Report:
uniQure Advancing AMT-130 Development in the New Year
Huntington's Disease Society of America-NC Chapter- January 2018- Chapter News!! -
Pitt County United Way Building
226 West 8th
STATEMENT BY LOUISE VETTER, PRESIDENT & CEO OF THE HUNTINGTON’S DISEASE SOCIETY OF AMERICA
REGARDING IONIS-HTTRx ANNOUNCEMENT
New York, NY, December 11, 2017 –... Today, the Huntington’s disease community achieved a goal that would not have been possible without the support and dedication of the families, physicians and researchers who passionately pursue a treatment for Huntington’s disease (HD). Ionis’ announcement of the completion of the Phase 1/2a study of IONIS-HTTRX is a historic moment in the fight against HD as it represents the successful completion of the first trial to treat the underlying cause of Huntington’s disease, the genetic mutation itself.
The fact that levels of mutant huntingtin were reduced in correlation to the dose of IONIS-HTTRx that was given is significant, and the fact that participants in this first Phase 1/2a study are able to continue on the drug through open label extension gives us optimism regarding its safety.
As the next phase of clinical study of IONIS-HTTRx gets underway, we look forward to continuing to partner with Roche and the many dedicated clinicians and scientists who work tirelessly to bring greater help and hope to Huntington’s families everywhere. We know families will have many questions about what happens next. We always recommend you speak with your doctor about any medical questions you may have. HDTrialFinder.org and HDSA.org will continue to provide the timeliest information regarding development of meaningful treatments for HD.
READ COMMUNITY ANNOUNCEMENT: http://hdsa.org/…/breaking-news-update-on-the-status-of-th…/